Exclusive: ASA calls number of parallel probes ‘significant’ and describes tackling issue as ‘priority’ after it issued ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...

Outside the game, commercials are a big part of Super Bowl Sunday. Companies pay large amounts of money for their ...

It shows visuals of existing weight loss medications known as GLP-1s, including injection pens that look like Novo Nordisk's blockbuster diabetes drug Ozempic ... an injection pen with distinctive ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Novo Nordisk also sells semaglutide as Ozempic for diabetes in the UK ... and is currently available in the original singe-dose pen-injector format. Mounjaro has already been launched in other ...